Skip to main
NDRA

NDRA Stock Forecast & Price Target

NDRA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ENDRA Life Sciences Inc. is developing Thermo Acoustic Enhanced UltraSound (TAEUS), aimed at providing a cost-effective diagnostic tool for Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) that currently lacks practical solutions. The company's technology is anticipated to receive FDA approval within the next year, which analysts believe could lead to a significant increase in stock value, as reflected in a positive net present value (NPV) analysis indicating considerable upside potential. Furthermore, TAEUS is expected to enhance the diagnosis and monitoring of liver diseases more accurately and cost-effectively than existing methods, creating a strong market demand for its application.

Bears say

ENDRA Life Sciences Inc reported a net loss of $1.6 million for the period, equating to an earnings per share (EPS) of $(2.10), which fell short of previously estimated $(1.95). The company's financial outlook is marred by persistent losses and the reiteration of risks associated with balance sheet and liquidity challenges, potential difficulties in demonstrating the safety and efficacy of its products, and uncertainties regarding regulatory approvals. Additionally, the competitive landscape along with shifting investor sentiment in the biotech and medtech sectors poses further risks to the company's ability to commercialize its technology and secure adequate reimbursement, leading to a negative perspective on the stock's future performance.

NDRA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ENDRA Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ENDRA Life Sciences (NDRA) Forecast

Analysts have given NDRA a Strong Buy based on their latest research and market trends.

According to 1 analysts, NDRA has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ENDRA Life Sciences (NDRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.